EUCTR2007-005115-26-AT进行中（未招募）不适用
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control, Dose-Ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of SKY0402 via Local Infiltration for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplasty
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female, = 18 and = 75 years of age at the Screening Visit.
- •Female subjects only: Postmenopausal, surgically sterile, or willing to use acceptable means of contraception for at least 30 days after surgery including any of the following: hormonal contraceptives (e.g., oral, injectable, implantable starting at least 30 days before study drug administration), effective double-barrier methods (e.g., condoms with spermicide), intrauterine device, lifestyle with a personal choice of abstinence, nonheterosexual lifestyle, or a strictly monogamous relationship with a partner who has had a vasectomy.
- •Scheduled to undergo primary unilateral TKA under general anesthesia.
- •American Society of Anesthesiology (ASA) Physical Classification System class 1-3 (See Appendix A for details).
- •Able and willing to comply with all study visits and procedures.
- •Able to speak, read, and understand the language of the Informed Consent, study questionnaires, and other instruments used for collecting subject-reported outcomes, in order to enable accurate and appropriate responses to pain scales and other required study assessments.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Pregnancy, nursing, or planning to become pregnant during the study or within one month after dosing.
- •Use of any of the following medications within the times specified before surgery:
- •Long-acting opioid medication within 3 days.
- •Any opioid medication within 24 hours.
- •Concurrent, painful, physical condition or concurrent surgery that may require analgesic treatment in the postoperative period for pain that is not strictly related to the surgical site administered study treatment, and which may confound the postoperative assessments (e.g., significant pain from other joints, chronic neuropathic pain, concurrent contralateral TKA, concurrent foot surgery, etc.).
- •Body weight less than 50 kilograms (110 pounds) or morbid obesity.
- •Contraindication to any of the pain-control agents planned for postoperative use (e.g., acetaminophen, morphine, oxycodone, ketorolac).
- •Contraindication to epinephrine, such as concurrent administration of monoamine oxidase (MAO) inhibitors or antidepressants of amitriptyline or imipramine types, conditions where the production or exacerbation of tachycardia could prove fatal (e.g., poorly controlled thyrotoxicosis or severe heart disease), or any other pathological conditions that might be aggravated by the effects of epinephrine.
- •Administration of an investigational drug within 30 days or 5 elimination half-lives of such investigational drug, whichever is longer, prior to study drug administration, or planned administration of another investigational product or procedure during the subject’s participation in this study.
- •History of, suspected, or known addiction to or abuse of illicit drug(s), prescription medicine(s), or alcohol within the past 2 years.
- •Uncontrolled anxiety, schizophrenia, or other psychiatric disorder that, in the opinion of the Investigator, may interfere with study assessments or compliance.
- •Current or historical evidence of any clinically significant disease or condition, especially cardiovascular or neurological conditions that, in the opinion of the Investigator, may increase the risk of surgery or complicate the subject’s postoperative course.
- •Significant medical conditions or laboratory results that, in the opinion of the Investigator, indicate an increased vulnerability to study drugs and procedures, and expose the subject to an unreasonable risk as a result of participating in this clinical trial, such as: debilitating diseases, acute illnesses, hypotension, partial or complete conduction block, impaired cardiac function, untreated hypertension, advanced arteriosclerotic heart disease, cerebral vascular insufficiency, pre-existing abnormal neurological or neuromuscular disease (e.g., epilepsy, myasthenia gravis), advanced liver disease, severe renal impairment, advanced diabetes, comorbid conditions associated with an immunocompromised status, such as blood dyscrasias, HIV/AIDS, or recent chemotherapy.
- •In addition, the subject will be ineligible to receive study drug if he or she meets the following criterion during surgery:
- •Any clinically significant event or condition uncovered during surgery (e.g., excessive bleeding), which occurs before study drug administration, that might render the subject medically unstable or complicate the subject’s postoperative course.
研究者
相似试验
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Control, Dose-Ranging Study to Evaluate the Safety, Efficacy, and Comparative Systemic Bioavailability of a Single Administration of SKY0402 via Local Infiltration for Prolonged Postoperative Analgesia in Subjects Undergoing Total Knee Arthroplastypost-operative pain managementEUCTR2007-005115-26-DEPacira Pharmaceuticals Inc.100
进行中（未招募）
1 期
Efficacy and Safety Study of Benralizumab for Patients with Severe Nasal Polyposisasal polyposisMedDRA version: 20.0Level: LLTClassification code 10028754Term: Nasal polypSystem Organ Class: 100000004855EUCTR2017-003675-61-ATAstraZeneca AB400
进行中（未招募）
1 期
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Patients Who Did Not Respond to Prior Preventive Migraine TreatmentsEUCTR2017-002441-30-DKTeva Branded Pharmaceutical Products R&D, Inc.838
进行中（未招募）
1 期
A Study to Test if Fremanezumab is Effective in Preventing Migraine in Patients Who Did Not Respond to Prior Preventive Migraine Treatmentsepisodic and chronic migraineMedDRA version: 20.0 Level: HLT Classification code 10027603 Term: Migraine headaches System Organ Class: 100000004852EUCTR2017-002441-30-CZTeva Branded Pharmaceutical Products R&D, Inc.838
进行中（未招募）
3 期
A Study to Compare Efficacy and Safety of BAT2306 with Cosentyx in Patients with Moderate to Severe Plaque PsoriasisModerate to Severe Plaque PsoriasisJPRN-jRCT2051220123Yoo EunHye60